News

08/01/2011

A stem cell trial in the United Kingdom has just received funding to initiate a phase II trial. This study will treat relapsing-remitting patients with autologous, mesenchymal stem cells administered intravenously. This study is similar to the MSRCNY stem cell proposal, except that, in the MSRCNY planned trial, we will be using neural progenitor cells which are derived from mesenchymal stem cells  and the cells would be administered intrathecally (directly into the spinal fluid). We eagerly... more

08/01/2011

Dr. Andrew Sylvester presented the following article at Journal Club this week: “Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS” by Kowarik et al in Neurology (2011). The discussion focused on the effect of fingolimod on various immune cell types in the brain and cerebrospinal fluid.

07/22/2011

We are saddened to report that Amber Peskin, a valued nurse here for over three years, will be leaving the practice in mid-August. As some of you know, Amber is a new mom and wanted to relocate back to her hometown of New Orleans to be closer to her family. We all wish Amber the best and will miss her very much.

07/22/2011

Dr. Subramaniam Sriram, from Vanderbilt University, spoke at Grand Rounds this week. His topic was the role of the innate immune system in the development and pathogenesis of MS and he spoke a good deal about his research on nitric oxide. Following his presentation, we discussed how Methotrexate modulates nitric oxide pathways and may be an additional mechanism of its benefit in progressive forms of MS. We will be supplying Dr. Sriram with frozen CSF samples of patients before and after... more

07/22/2011

We are very pleased to announce that the IMSMP/MSRCNY has had eight posters accepted at this year’s ECTRIMS conference. ECTRIMS is the European Committee for Treatment and Research in Multiple Sclerosis and this year’s meeting will be in Amsterdam in October. Dr. Sadiq and several laboratory personnel will be in attendance. http://www.ectrims.eu/

05/29/2011

After speaking with the FDA, they have asked for additional long term safety experiments in a larger animal model.  This process will occur over the course of 2 years and cost an estimated 3 million dollars.  We are now going to start the process of obtaining funding to conduct these experiments.

We thank you for your understanding and hope you will help support our ongoing research at MSRCNY.

05/29/2011

We're very excited that construction is underway on our 3rd floor expansion!

Please excuse the noise and appearance while we undergo this transition. 

05/29/2011

NEW YORK, NY, January 19,2010 - The International Multiple Sclerosis Management Practice (IMSMP), a 34,000 square foot research and treatment center dedicated to MS, today announced that it has signed a lease for an additional 48,000 square feet.  This makes it the largest establishment in the world committed to discovering the cause and cure for MS. 

The practice expansion will include a Wellness Center and two MRI machines, white the Research Center will expand to include a Stem... more

05/29/2011

Here is an excerpt from the article on MS. The entire supplement is available at the bottom of the page.

Multiple sclerosis (MS) is a disease  of the central nervous system. While the cause isn’t yet known, it’s believed to be an autoimmune disease, which means that in MS the immune system attacks healthy tissue in the body—in this case, the myelin that surrounds and protects the nerves. The damaged myelin forms the scar tissue (sclerosis) that gives the disease its name. When any... more

Pages

IMSMP

Because you deserve only the best in MS healthcare. Experience the difference.

Newsletter Sign Up

Join our mailing list today!  Receive the latest information and updates happening in MS research, treatment and care including, Healing MS, the IMSMP newsletter.

* We don’t share your information with anyone.